Tarnow L - Search Results

1

Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P; PREDICTIONS Network. Rossing K, et al. Among authors: tarnow l. J Am Soc Nephrol. 2008 Jul;19(7):1283-90. doi: 10.1681/ASN.2007091025. Epub 2008 Apr 30. J Am Soc Nephrol. 2008. PMID: 18448586 Free PMC article.

2

Smoking and progression of diabetic nephropathy in type 1 diabetes.

Hovind P, Rossing P, Tarnow L, Parving HH. Hovind P, et al. Among authors: tarnow l. Diabetes Care. 2003 Mar;26(3):911-6. doi: 10.2337/diacare.26.3.911. Diabetes Care. 2003. PMID: 12610058

3

Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes.

Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, Parving HH. Hovind P, et al. Among authors: tarnow l. Diabetes Care. 2003 Apr;26(4):1258-64. doi: 10.2337/diacare.26.4.1258. Diabetes Care. 2003. PMID: 12663607

4

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points.

Parving HH, Andersen S, Jacobsen P, Christensen PK, Rossing K, Hovind P, Rossing P, Tarnow L. Parving HH, et al. Among authors: tarnow l. Semin Nephrol. 2004 Mar;24(2):147-57. doi: 10.1016/j.semnephrol.2003.11.003. Semin Nephrol. 2004. PMID: 15017527 Review.

5

Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study.

Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I, Binder C, Parving HH. Hovind P, et al. Among authors: tarnow l. BMJ. 2004 May 8;328(7448):1105. doi: 10.1136/bmj.38070.450891.FE. Epub 2004 Apr 19. BMJ. 2004. PMID: 15096438 Free PMC article.

6

Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy.

Hovind P, Tarnow L, Rossing P, Carstensen B, Parving HH. Hovind P, et al. Among authors: tarnow l. Kidney Int. 2004 Sep;66(3):1180-6. doi: 10.1111/j.1523-1755.2004.00870.x. Kidney Int. 2004. PMID: 15327415 Free article.

7

Progression of nephropathy in type 2 diabetic patients.

Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Rossing K, et al. Among authors: tarnow l. Kidney Int. 2004 Oct;66(4):1596-605. doi: 10.1111/j.1523-1755.2004.00925.x. Kidney Int. 2004. PMID: 15458456 Free article.

8

Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy.

Andersen S, van Nieuwenhoven FA, Tarnow L, Rossing P, Rossing K, Wieten L, Goldschmeding R, Parving HH. Andersen S, et al. Among authors: tarnow l. Kidney Int. 2005 Jun;67(6):2325-9. doi: 10.1111/j.1523-1755.2005.00337.x. Kidney Int. 2005. PMID: 15882275 Free article.

9

Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.

Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk C, Tarnow L, Parving HH. Persson F, et al. Among authors: tarnow l. Diabetes. 2006 Dec;55(12):3550-5. doi: 10.2337/db06-0827. Diabetes. 2006. PMID: 17130503 Clinical Trial.

10

Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy.

Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving HH, Rossing P. Lajer M, et al. Among authors: tarnow l. Diabetes Care. 2008 Apr;31(4):747-52. doi: 10.2337/dc07-1762. Epub 2007 Dec 27. Diabetes Care. 2008. PMID: 18162497

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

303 results

Search Page

Filters